🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📸Impressionen vom 75. #DGU23 #Kongress im #CCL in #Leipzig Axel S. Merseburger GeSRU BvDUrologie DGU UroForum Urologie Marburg European Association of Urology (EAU) onkowissen EAU Edu Platform UROONCO Deutsche Krebshilfe JOURNAL ONKOLOGIE @arztcommunity änd – Ärztenachrichtendienst @MT_Onkologie DGAndrologie onkowissen @interplan_de

Important news #bladdercancer merck.com/news/merck-ann…

Der Protest der Urologen gegen die aktuelle Gesundheitspolitik. #DGU23 #urologie #uroforum Axel S. Merseburger DGU Kongress

Now online at Lancet Oncology - final results of TITAN-RCC demonstrating added value of ipilimumab in RCC. authors.elsevier.com/a/1hw4d5EIIgLq…

Now online at European Urology: Impact of prior cytoreductive nephrectomy in patients receiving Axitinib+Avelumab vs Sunitinib in JAVELIN RENAL 101 authors.elsevier.com/sd/article/S03…

#ESMO23 is off to a great start. Prof. Prof. Dr. med. Diana Lüftner and Prof. Axel S. Merseburger discuss their personal highlights so far and what they are looking forward to the next couple of days. Stay tuned! #esmo2023 #oncology #highlights #breastcancer #urology ESMO - Eur. Oncology

Data from the phase 2 TITAN-TCC trial suggest that high-dose ipilimumab may be an appropriate salvage option for selected patients receiving nivolumab monotherapy as second-line treatment for metastatic urothelial carcinoma. Marc-Oliver Grimm Mitteldeutsches Krebszentrum (CCCG)

Regarding the TITAN-TCC approach, 48% (Clopper-Pearson exact 90% CI, 0.34-0.61; 1-sided P <.001) of patients in first-line cohort 1 achieved a response, and 7% had a complete response. #blcsm | Marc-Oliver Grimm cancernetwork.com/view/nivolumab…

Post-progression survival of patients with #mHSPC who received darolutamide or PBO: Post hoc analysis of #ARASENS. Presented by Marc-Oliver Grimm. #ASCO24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3Kp59hV ASCO

Simon C Colin H Adam Sharp Mark Wildgust (he/him) 💙alison birtle As an answer to that question, I quote the great Gary Lineker "Football is a simple game. Twenty-two men chase a ball for 90 minutes and at the end, the Germans always win", Clara Steiner Michael Staehler Ken Herrmann Marc-Oliver Grimm

Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…

Spannende Daten zum #Prostatakarzinom vom #ESMO24. Diskutiert von den #onkowissenTV Fachleuten! Nicht verpassen! Jozefina Casuscelli Marc-Oliver Grimm Viktor Grünwald Peter J. Goebell Boris Hadaschik Ken Herrmann philipp ivanyi Axel S. Merseburger @martin_schostak Derya Tilki, MD

📽️We are live! Watch our reports from #ESMO24, for free and on demand: high5oncology.tv/meeting-covera… #high5oncologyTV Stephen V Liu, MD Dr Riyaz Shah Frank Griesinger Martin Reck Noemi Reguart Lizza Hendriks Nicolas Girard denis Moro-Sibilot Hossein Borghaei, DO Sacha Rothschild joaquim bellmunt Anders Bjartell

Huge congrats to Tom Powles Barts Cancer Centre who is changing GU Oncology landscape 1 trial at a time, all while doing other leadership things ESMO - Eur. Oncology Annals of Oncology Uromigos + much more …

Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. pfizer.com/news/press-rel…

Looking forward meeting Boris Hadaschik Ken Herrmann Marc-Oliver Grimm erikbelleville at poster L27 "Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer" Study aims to enroll 5,000 patients in Germany #GU25 #ASCOGU25 #mHSPC #mCRPC OncoAlert

🚀 ASCO GU 2025: high5oncologyTV reporting live! 🎥🔬 📢 The latest breakthroughs in GU oncology – straight from ASCO GU 2025! Our high5oncologyTV experts are on-site, bringing you exclusive insights into the most important studies and results. 📅 From February 16, watch our

The IMDC prognostic criteria is dynamic Tian Zhang, MD, MHS . A number of factors determine group allocation including, extent of tumour and progression. This accounts for patients moving across groups during progression. It’s not surprising it struggles to predict IO response #GU25

💫🌟The Uromigos are LIVE from #GUTrends25 Tom Powles & Brian Rini, MD break down the #UromigosScore 🧮 for Progression after 2L in #BladderCancer How does it work? 🌐 18 experts 🔢 Score treatments from 0 to 3 📊 Mean score reflects expert consensus Key insights: ➡️ Scenarios

Dra. María Natalia Gandur Quiroga Uromigos Tom Powles Brian Rini, MD These are the results… (be advise, low quality images). Tom Powles at #GUtrends25